The bioavailability is greater in rectal administration than oral administration (relative bioavailability = 1.26) (ages 2-8 years, N=26) [Van de Maarel 2004]
Two studies (n=21, ages 4 -15 jyears) reported the following pharmocokinetic parameters: [Romsing 2001; Korpela 1990]
| Cmax after oral administration | 0.5-4.5 µg/ml |
| Tmax after oral administration | 1.5-3 hour |
| t1/2 | ± 0.5-2 hour |
| Cl/F | 5.6-18.4 ml/min/kg |
| Vd/F | 443-1089 ml/kg |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Painmanagement (among which Juvenile Idiopathic Arthritis (JIA)) |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Adjustment in renal impairment as specified:
Risk-factors are: heart failure, liver cirrhosis, nephrotic syndrome, chronic kidney disease, causes leading to dehydration (e.g. summer heat), use of other drugs decreasing renal function, like diuretics or RAAS inhibitors.
NSAIDs (including COX-2 inhibitors) can cause acute renal failure by decreasing renal perfusion (by hypovolaemia). Normally, an increased prostaglandin synthesis in the kidneys prevents a rapid decrease in renal perfusion; however, NSAIDs disturb this compensating mechanism. Decreased renal perfusion also leads to water and salt retention, resulting in the occurrence or worsening of hypertension and heart failure.
Haemodialysis / continuous venovenous haemodialysis or haemo(dia)filtration:
Patients undergoing dialysis have a higher bleeding risk, probably related to an abnormal platelet function. The bleeding risk can be increased by the use of low molecular weight heparines at the start of haemodialysis to prevent coagulation in the extracorporeal circulation.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Diclofenac slows the thrombocyte aggregation. This process is reversible. Gastritis
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
When used post-operatively, be aware of the elevated risk of further bleeding. Liquids for injection may contain benzyl alcohol.
Be aware of the possibility of exacerbation of asthma (do not use in children with acute or active asthma). Caution is needed in impaired liver function and elevated risk of renal impairment and concomitant use of nephrotoxic drugs.
In exceptional cases, varicella can lead to serious infectious complications of the skin and soft tissues. To date, it cannot be ruled out that NSAIDs contribute to the worsening of these infections. It is therefore recommended not to use ibuprofen in cases of varicella(Prescrire Internat 2010).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Acetic acid derivatives and related substances | ||
|---|---|---|
| M01AB01 | ||
| Oxicams | ||
|---|---|---|
| M01AC01 | ||
| Propionic acid derivatives | ||
|---|---|---|
| M01AE14 | ||
| M01AE01 | ||
| M01AE02 | ||
| Fenamates | ||
|---|---|---|
| M01AG01 | ||
| Coxibs | ||
|---|---|---|
| M01AH01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.